

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Khouzami Carim V</u> (Last) (First) (Middle) <u>10 S. DEARBORN STREET</u> <u>54TH FLOOR</u> (Street) <u>CHICAGO IL 60603</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>12/02/2019</u>	3. Issuer Name and Ticker or Trading Symbol <u>EXELON CORP [EXC]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>CEO of BGE</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>11,008</u>	<u>D</u>	
<u>Common Stock (401k shares)</u>	<u>644</u>	<u>I</u>	<u>By Exelon Employee Savings Plan (401k plan)</u>

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
<u>Restricted Stock Unit Award (01/30/2017)</u>	<u>(1)</u>	<u>(1)</u>	<u>Common stock</u> <u>1,278</u>	<u>(1)</u>	<u>D</u>	
<u>Restricted Stock Unit Award (01/29/2018)</u>	<u>(2)</u>	<u>(2)</u>	<u>Common stock</u> <u>2,257</u>	<u>(2)</u>	<u>D</u>	
<u>Restricted Stock Unit Award (02/04/2019)</u>	<u>(3)</u>	<u>(3)</u>	<u>Common stock</u> <u>2,652</u>	<u>(3)</u>	<u>D</u>	
<u>Deferred Compensation Equivalent Shares</u>	<u>(4)</u>	<u>(4)</u>	<u>Common stock</u> <u>639</u>	<u>(4)</u>	<u>D</u>	

Explanation of Responses:

- Remaining 1/3 increment of annual restricted stock unit (RSU) award granted in 2017 pursuant to the Exelon Long Term Incentive Plan; each award vests in 1/3 increments on the date of the Compensation & Leadership Development Committee's January meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
- Remaining 2/3 increment of annual RSU award granted in January 2018 pursuant to the Exelon Long Term Incentive Plan; each award vests in 1/3 increments on the date of the Compensation & Leadership Development Committee's January meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
- Annual RSU award granted in February 2019 pursuant to the Exelon Long Term Incentive Plan; each award vests in 1/3 increments on the date of the Compensation & Leadership Development Committee's January meeting in the first, second and third years after the award was granted. Award balances accrue additional units through automatic dividend reinvestment, which vest on the same schedule as the underlying award.
- Phantom share equivalents representing units held in the Exelon stock fund in a multi-fund, non-qualified deferred compensation plan. The Exelon stock fund is a unitized fund that consists of Exelon common stock and short term investments. Units of the fund will be settled upon the reporting person's termination of service for any reason. Units will be settled in cash. Units are acquired through regular periodic contributions, company matching contributions and the reinvestment of dividend equivalents. The balance of phantom share equivalents may fluctuate from time to time due to fluctuations in the fund composition.

Remarks:

Elizabeth M. Hensen,
Attorney-in-Fact for Carim V. Khouzami 12/11/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

EXELON CORPORATION
SECTION 16 REPORTING POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Carter C. Culver, Katherine A. Smith, Brian Buck, Elizabeth M. Hensen and Tom Boin, signing singly, the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and or director of Exelon Corporation ("Exelon"), all reports to be filed by the undersigned pursuant to Section 16(a) of the Securities Exchange Act of 1934 and the rules promulgated thereunder (including EDGAR Form ID, Forms 3, 4, and 5 and any successor forms) (the "Section 16 Reports");

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Section 16 Report, complete and execute any amendment or amendments thereto, and timely file such report with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is Exelon assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Section 16 Reports with respect to the undersigned's holdings of and transactions in securities issued by Exelon, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 6th day of December 2019.

Signature: /s/ Carim V. Khouzami

Print Name: Carim V. Khouzami